Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 7Plasma cell 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 3Vascular Diseases 2Paraproteinemias 2Lymphoproliferative Disorders 2Immunoproliferative Disorders 2Hemostatic Disorders 2Hemorrhagic Disorders 2Hematologic Diseases 2Blood Coagulation Disorders 2Neoplasms, Plasma Cell 1

Interventions

Tacrolimus 4Epoetin Alfa 4Busulfan 4fludarabine 3Darbepoetin alfa 3Bortezomib 3fludarabine phosphate 2dacetuzumab 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Lenalidomide 2Early Intervention, Educational 2Dexamethasone 2Antilymphocyte Serum 2Alemtuzumab 2venetoclax 1trametinib 1ruxolitinib 1plerixafor 1isatuximab 1ficlatuzumab 1ferrous sulfate 1ferric gluconate 1ethanolamine oleate 1dabrafenib 1Vorinostat 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Tinzaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × dacetuzumab × Plasma cell × Clear all
NCT00079716 2014-12-18

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Seagen Inc.

Phase 1 Completed
44 enrolled
LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Seagen Inc.

Phase 1 Completed
36 enrolled
LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡